PCI Biotech Holding Logo

PCI Biotech Holding

PCIB | OL

Overview

Corporate Details

ISIN(s):
NO0010405640
LEI:
5967007LIEEXZXFIGG77
Country:
Norway
Address:
Ullernchausséen 64, 0379 OSLO
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

PCI Biotech Holding is a biopharmaceutical company developing therapeutic products based on its proprietary Photochemical Internalisation (PCI) technology. This platform is designed to enable the efficient intracellular delivery of therapeutic molecules. The company's development programs are focused on several areas, including immunotherapy and dermatology, with the photosensitiser fimaporfin (Amphinex) as a key product candidate for cancer treatment. Additionally, PCI Biotech applies its technology to bioprocessing, aiming to advance and improve the manufacturing of viral vectors for gene therapies. The technology originated from research at the Oslo Radium Hospital.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for PCI Biotech Holding. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-18 20:39
Regulatory News Service
PCI Biotech announces discontinuation of development of the PCL technology and …
English 3.4 KB
2025-05-22 09:45
Post-Annual General Meeting Information
PCI Biotech: Minutes of Annual General Meeting 2025
Norwegian 449.8 KB
2025-05-22 09:45
Post-Annual General Meeting Information
PCI Biotech: Minutes of Annual General Meeting 2025
English 866 bytes
2025-05-20 20:08
Declaration of Voting Results & Voting Rights Announcements
PCI BIotech: Disclosure of voting rights for Chair of the Board
English 1.2 KB
2025-04-30 08:00
Pre-Annual General Meeting Information
Notice of Annual General Meeting 2025
Norwegian 188.6 KB
2025-04-30 08:00
Pre-Annual General Meeting Information
Notice of Annual General Meeting 2025
Norwegian 146.9 KB
2025-04-30 08:00
Pre-Annual General Meeting Information
Notice of Annual General Meeting 2025
English 167.8 KB
2025-04-30 08:00
Pre-Annual General Meeting Information
Notice of Annual General Meeting 2025
English 208.0 KB
2025-04-30 08:00
Pre-Annual General Meeting Information
Notice of Annual General Meeting 2025
English 977 bytes
2025-04-24 15:30
Annual Report (ESEF)
PCI Biotech Holding ASA: Annual Report 2024
English 5.4 MB
2025-04-24 15:30
Annual Report
PCI Biotech Holding ASA: Annual Report 2024
English 1.2 MB
2025-04-24 15:30
Report Publication Announcement
PCI Biotech Holding ASA: Annual Report 2024
English 908 bytes
2025-02-27 06:00
Investor Presentation
PCI Biotech full year 2024 interim results
English 2.5 MB
2025-02-27 06:00
Interim Report
PCI Biotech full year 2024 interim results
English 978.4 KB
2025-02-27 06:00
Report Publication Announcement
PCI Biotech full year 2024 interim results
English 6.0 KB

Automate Your Workflow. Get a real-time feed of all PCI Biotech Holding filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for PCI Biotech Holding via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
ONCODESIGN Logo
Develops precision cancer therapies and diagnostics targeting resistance and metastasis.
France ALONC
Oncodesign Precision Medicine S.A Logo
Develops therapies & diagnostics for resistant and metastatic cancers.
France ALOPM
Oncoinvent ASA Logo
Developing alpha-emitting radiopharmaceuticals like Radspherin® for localized cancer treatment.
Norway OCIN
OncoZenge AB Logo
Developing a non-opioid lozenge for oral pain relief in cancer patients.
Sweden ONCOZ
Onxeo Logo
Developing precision therapies for complex diseases using a proprietary single-domain antibody platform.
France ALONX
OPTIBIOTIX HEALTH PLC Logo
Develops microbiome-modulating ingredients and supplements to manage chronic lifestyle diseases.
United Kingdom OPTI
Oramed Pharmaceuticals Inc. Logo
Developing oral drug delivery systems to replace injections, like an oral insulin capsule.
Israel ORMP
Oryzon Genomics S.A. Logo
Advancing epigenetic therapeutics for oncology and central nervous system disorders.
Spain ORY
OSE Immunotherapeutics Logo
Developing first-in-class immunotherapies for immuno-oncology and immuno-inflammation.
France OSE
Ovoca Bio Plc Logo
Clinical-stage biopharma developing novel treatments for female sexual dysfunction.
Ireland OVXA